Breaking Finance News

Neos Therapeutics (NDAQ:NEOS) target price lowered to $8.00, issued a report today by UBS Securities

Yesterday Neos Therapeutics (NDAQ:NEOS) traded -3.95% lower at $7.22. The company’s 50-day moving average is $6.03 and its 200-day moving average is $6.56. The last stock close price is up 11.24% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 657,823 shares of the stock were exchanged, up from an average trading volume of 309,570

Neos Therapeutics (NDAQ:NEOS) had its target price lowered to $8.00 by UBS Securities in a report released 3/20/2017. The new target price indicates a possible upside of 0.11% based on the company's last stock close price.

See Chart Below

Neos Therapeutics (NDAQ:NEOS)

Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $11.50 The company’s market cap is currently $0.

In addition to UBS Securities reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $22.50 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Neos Therapeutics (NDAQ:NEOS)

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.